ICT01是一种靶向抗BTN3A的单克隆抗体,它可选择性地激活γ9δ2 T细胞,目前正在进行中的I/IIa期EVICTION试验(NCT04243499)中研究其对晚期实体肿瘤和血液系统肿瘤的疗效。研究发现,ICT01激活的γ9δ2 T细胞在体内外均能杀伤急性髓系...
ICT01是一种靶向抗BTN3A单抗(mAb),可选择性激活γ9δ2 T细胞,目前正在进行中的1/2a期EVICTION试验(NCT04243499)中对晚期实体癌和血液系统癌进行研究。 众所周知,ICT01激活的γ9δ2 T细胞在体外和体内均可杀伤急性髓系白血病(AML)...
BTN3A单抗ICT01 ICT01是一种能够选择性激活γ9δ2 T细胞的人源化抗BTN3A单克隆抗体,既可以作为单药方案,也能够与派姆单抗联合应用。 根据目前公开的Ⅰ/Ⅱ期EVICTION试验(NCT04243499)初步研究结果,接受ICT01单药治疗的19例患者,疾病控制率31.6%;接受ICT01联合派姆单抗方案治疗的8例患者,疾病控制率62.5%。 值得注...
Background: ICT01, an anti-BTN3A mAb, selectively activates γ9δ2 T cells resulting in remodeling of the tumor microenvironment by activated γ9δ2 T, CD8 T, and NK cells (EVICTION- NCT04243499; AACR 2022 CT188). Response to ICT01 depends on the baseline number of γ9δ2 T cells ...
EVICTION is an open-label Phase I/IIa trial assessing ICT01, a humanized anti-BTN3A monoclonal antibody that selectively activates γ9δ2 T cells, as a monotherapy in solid and hematological tumors, and as a combination therapy with pembrolizumab in solid ...
BTN3A单抗ICT01 ICT01是一种能够选择性激活92 T细胞的人源化抗BTN3A单克隆抗体,既可以作为单药方案,也能够与派姆单抗联合应用。 根据目前公开的Ⅰ/Ⅱ期EVICTION试验(NCT04243499)初步研究结果,接受ICT01单药治疗的19例患者,疾病控制率31.6%;接受ICT01联合派姆单抗方案治疗的8例患者,疾病控制率62.5%。
Tumor biopsies (baseline, Day 28) were used for immunohistochemistry of BTN3A and tumor-infiltrating lymphocytes, and gene expression profiling. Efficacy evaluations were conducted every 8 weeks. Results ICT01 monotherapy dose escalation (20g to 200mg IV ICT01 Q3W) in solid tumor patients (Group ...
Background ICT01 is an anti-BTN3A mAb that selectively activates γ9δ2 T cells to orchestrate a robust antitumor immune response of the innate and adaptive immune systems that leads to solid tumor infiltration of activated γ9δ2 T cells, CD8 T cells, and NK cells. (EVICTION trial (NCT...
The anti-BTN3A mAb ICT01 selectively activates 纬9未2 T cells and is being studied in the phase1/2a EVICTION Trial (NCT04243499). In preclinical studies, ICT01 induces upregulation of PD-1 on 纬9未2 T-cells and combination with pembrolizumab leads to enhanced cancer cell killing, ...
Background ICT01 is a first-in-class anti-BTN3A mAb that selectively activates γ9δ2 T cells, leading to remodeling of the tumor microenvironment by activated γ9δ2 T, CD8 T, and NK cells (EVICTION-NCT04243499). However, many cancer patients have very low circulating γ9δ2 T cells ...